Discover 1,971 paid clinical trials in Boca Raton, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,971
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing
for
Diabetic Foot Ulcers (DFUs),
Location: Tamarac FL
Sponsor: Reprise Biomedical, Inc.
Sex: All
Age: 18+
Code: NCT06939686
Recruiting
Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
for
Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs),
Location: Tamarac FL
Sponsor: Reprise Biomedical, Inc.
Sex: All
Age: 18+
Code: NCT06939673
Recruiting
Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers
for
Peripheral Artery Disease,
Location: Tamarac FL, Deerfield Beach FL, South Miami FL,
Sponsor: AnGes USA, Inc.
Sex: All
Age: 18+
Code: NCT04267640
Phase2, Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for
Non-small Cell Lung Cancer
Location: Tamarac FL, West Palm Beach FL, Pembroke Pines FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06561386
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
for
Glomerular Disease, Proteinuria
Location: Lauderdale Lakes FL, Tampa FL, Columbus GA,
Sponsor: Angion Biomedica Corp
Sex: All
Age: 18+
Code: NCT04939116
Phase2, Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment